Shanghai RAAS Blood Products Co Ltd Class A Strategic Asset Allocation Index
Shanghai RAAS Blood Products Co Ltd Class A strategic asset allocation index. Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Strategic Asset Allocation Index of 4.4% as of September 2023. Strategic assets (PP&E of CN¥1.32 Billion plus long-term investments of CN¥-) total CN¥1.32 Billion, measured against net assets of CN¥29.82 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Shanghai RAAS Blood Products Co Ltd Clas tangible book value ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Shanghai RAAS Blood Products Co Ltd Class A (2005–2022)
Strategic asset allocation index of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2022. This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Strategic Asset Allocation Index has evolved across 18 annual periods from 2005 to 2022. As of September 2023, the index stands at 4.4%, representing strategic assets of CN¥1.32 Billion against net assets of CN¥29.82 Billion CNY.
Shanghai RAAS Blood Products Co Ltd Class A Strategic Asset Allocation Index by Year (2005–2022)
Shanghai RAAS Blood Products Co Ltd Class A strategic asset allocation index by year from 2005 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2022, covering 18 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Shanghai RAAS Blood Products Co Ltd Clas stock valuation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 4.4% | CN¥1.28 Billion | CN¥1.28 Billion | CN¥- | CN¥28.81 Billion | ▼ -0.5 pp |
| 2021 | 4.9% | CN¥1.28 Billion | CN¥1.28 Billion | CN¥- | CN¥25.90 Billion | ▲ +0.0 pp |
| 2020 | 4.9% | CN¥1.23 Billion | CN¥1.23 Billion | CN¥- | CN¥25.13 Billion | ▼ -5.0 pp |
| 2019 | 9.9% | CN¥1.14 Billion | CN¥1.14 Billion | CN¥- | CN¥11.49 Billion | ▼ -0.4 pp |
| 2018 | 10.3% | CN¥1.13 Billion | CN¥1.13 Billion | CN¥- | CN¥10.90 Billion | ▲ +1.4 pp |
| 2017 | 8.9% | CN¥1.12 Billion | CN¥1.12 Billion | CN¥- | CN¥12.48 Billion | ▼ -1.0 pp |
| 2016 | 10.0% | CN¥1.17 Billion | CN¥1.17 Billion | CN¥- | CN¥11.73 Billion | ▲ +0.0 pp |
| 2015 | 10.0% | CN¥1.07 Billion | CN¥1.07 Billion | CN¥- | CN¥10.71 Billion | ▼ -2.3 pp |
| 2014 | 12.2% | CN¥1.06 Billion | CN¥1.06 Billion | CN¥- | CN¥8.62 Billion | ▼ -43.9 pp |
| 2013 | 56.1% | CN¥618.43 Million | CN¥618.43 Million | CN¥- | CN¥1.10 Billion | ▲ +2.1 pp |
| 2012 | 54.0% | CN¥550.93 Million | CN¥550.93 Million | CN¥- | CN¥1.02 Billion | ▲ +11.9 pp |
| 2011 | 42.2% | CN¥391.22 Million | CN¥391.22 Million | CN¥- | CN¥927.27 Million | ▲ +12.0 pp |
| 2010 | 30.2% | CN¥251.34 Million | CN¥251.34 Million | CN¥- | CN¥831.21 Million | ▲ +9.9 pp |
| 2009 | 20.3% | CN¥154.89 Million | CN¥154.89 Million | CN¥- | CN¥763.33 Million | ▲ +5.7 pp |
| 2008 | 14.6% | CN¥110.39 Million | CN¥110.39 Million | CN¥- | CN¥754.76 Million | ▼ -45.4 pp |
| 2007 | 60.0% | CN¥102.02 Million | CN¥102.02 Million | CN¥- | CN¥170.01 Million | ▲ +1.5 pp |
| 2006 | 58.5% | CN¥91.78 Million | CN¥91.78 Million | CN¥- | CN¥156.77 Million | ▲ +21.8 pp |
| 2005 | 36.7% | CN¥85.06 Million | CN¥85.06 Million | CN¥- | CN¥231.70 Million | — |